Rare Cancers Australia has released an updated 'counting the cost' report focused on achieving change through the current health technology assessment review but CEO Richard Vines has also called for greater transparency in the process.
'We talk about the cost of action, but we need to think about the cost of inaction'
September 28, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma -
Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant
June 19, 2025 - - Latest News -
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 - - Australian Biotech -
NZ Government expands access to melatonin and psilocybin
June 18, 2025 - - Latest News -
Imugene announces US patent allowance for onCARlytics
June 18, 2025 - - Australian Biotech